Indication
Treatment of adult patients with locally advanced or metastatic non squamous non-small cell lung cancer (NSCLC)
Loading your page…
Loading your page…
Carcinoma, Non-Small-Cell Lung
Marketing Authorisation Holder: Daiichi Sankyo Europe GmbH
INN: datopotamab deruxtecan
AI Drug & Interaction Analysis
Free account required
Ask Osler about Datopotamab deruxtecan Daiichi Sankyo: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.